385 related articles for article (PubMed ID: 20048219)
1. Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs.
Morrato EH; Druss B; Hartung DM; Valuck RJ; Allen R; Campagna E; Newcomer JW
Arch Gen Psychiatry; 2010 Jan; 67(1):17-24. PubMed ID: 20048219
[TBL] [Abstract][Full Text] [Related]
2. Metabolic screening in children receiving antipsychotic drug treatment.
Morrato EH; Nicol GE; Maahs D; Druss BG; Hartung DM; Valuck RJ; Campagna E; Newcomer JW
Arch Pediatr Adolesc Med; 2010 Apr; 164(4):344-51. PubMed ID: 20368487
[TBL] [Abstract][Full Text] [Related]
3. Assessment of monitoring for glucose and lipid dysregulation in adult Medi-Cal patients newly started on antipsychotics.
Barnett M; VonMuenster S; Wehring H; Popish S; McDonald K; Walker VM; Perry P
Ann Clin Psychiatry; 2010 Feb; 22(1):9-18. PubMed ID: 20196978
[TBL] [Abstract][Full Text] [Related]
4. Metabolic risk status and second-generation antipsychotic drug selection: a retrospective study of commercially insured patients.
Morrato EH; Cuffel B; Newcomer JW; Lombardo I; Kamat S; Barron J
J Clin Psychopharmacol; 2009 Feb; 29(1):26-32. PubMed ID: 19142103
[TBL] [Abstract][Full Text] [Related]
5. Small area variation and geographic and patient-specific determinants of metabolic testing in antipsychotic users.
Morrato EH; Druss BG; Hartung DM; Valuck RJ; Thomas D; Allen R; Campagna E; Newcomer JW
Pharmacoepidemiol Drug Saf; 2011 Jan; 20(1):66-75. PubMed ID: 21182154
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of baseline serum glucose and lipid testing in users of second-generation antipsychotic drugs: a retrospective, population-based study of Medicaid claims data.
Morrato EH; Newcomer JW; Allen RR; Valuck RJ
J Clin Psychiatry; 2008 Feb; 69(2):316-22. PubMed ID: 18251625
[TBL] [Abstract][Full Text] [Related]
7. Metabolic monitoring of patients prescribed second-generation antipsychotics.
Dhamane AD; Martin BC; Brixner DI; Hudson TJ; Said Q
J Psychiatr Pract; 2013 Sep; 19(5):360-74. PubMed ID: 24042242
[TBL] [Abstract][Full Text] [Related]
8. Effects of Food and Drug Administration warnings on antidepressant use in a national sample.
Olfson M; Marcus SC; Druss BG
Arch Gen Psychiatry; 2008 Jan; 65(1):94-101. PubMed ID: 18180433
[TBL] [Abstract][Full Text] [Related]
9. Risk of diabetes mellitus associated with atypical antipsychotic use among Medicaid patients with bipolar disorder: a nested case-control study.
Guo JJ; Keck PE; Corey-Lisle PK; Li H; Jiang D; Jang R; L'Italien GJ
Pharmacotherapy; 2007 Jan; 27(1):27-35. PubMed ID: 17192159
[TBL] [Abstract][Full Text] [Related]
10. Using antipsychotic agents in older patients.
Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
[TBL] [Abstract][Full Text] [Related]
11. Metabolic screening after the American Diabetes Association's consensus statement on antipsychotic drugs and diabetes.
Morrato EH; Newcomer JW; Kamat S; Baser O; Harnett J; Cuffel B
Diabetes Care; 2009 Jun; 32(6):1037-42. PubMed ID: 19244091
[TBL] [Abstract][Full Text] [Related]
12. [Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].
Bret P; Bret MC; Queuille E
Encephale; 2009 Apr; 35(2):129-38. PubMed ID: 19393381
[TBL] [Abstract][Full Text] [Related]
13. Changes in neuroendocrine and metabolic hormones induced by atypical antipsychotics in normal-weight patients with schizophrenia.
Popovic V; Doknic M; Maric N; Pekic S; Damjanovic A; Miljic D; Popovic S; Miljic N; Djurovic M; Jasovic-Gasic M; Dieguez C; Casanueva FF
Neuroendocrinology; 2007; 85(4):249-56. PubMed ID: 17570902
[TBL] [Abstract][Full Text] [Related]
14. Quality of monitoring for metabolic effects associated with second generation antipsychotics in patients with schizophrenia on public insurance.
Moeller KE; Rigler SK; Mayorga A; Nazir N; Shireman TI
Schizophr Res; 2011 Mar; 126(1-3):117-23. PubMed ID: 21168994
[TBL] [Abstract][Full Text] [Related]
15. Antipsychotics, glycemic disorders, and life-threatening diabetic events: a Bayesian data-mining analysis of the FDA adverse event reporting system (1968-2004).
DuMouchel W; Fram D; Yang X; Mahmoud RA; Grogg AL; Engelhart L; Ramaswamy K
Ann Clin Psychiatry; 2008; 20(1):21-31. PubMed ID: 18297583
[TBL] [Abstract][Full Text] [Related]
16. Risk for incident diabetes mellitus following initiation of second-generation antipsychotics among Medicaid-enrolled youths.
Rubin DM; Kreider AR; Matone M; Huang YS; Feudtner C; Ross ME; Localio AR
JAMA Pediatr; 2015 Apr; 169(4):e150285. PubMed ID: 25844991
[TBL] [Abstract][Full Text] [Related]
17. Metabolic Testing for Adults in a State Medicaid Program Receiving Antipsychotics: Remaining Barriers to Achieving Population Health Prevention Goals.
Morrato EH; Campagna EJ; Brewer SE; Dickinson LM; Thomas DS; Miller BF; Dearing J; Druss BG; Lindrooth RC
JAMA Psychiatry; 2016 Jul; 73(7):721-30. PubMed ID: 27167755
[TBL] [Abstract][Full Text] [Related]
18. Comparison of second-generation antipsychotic treatment on psychiatric hospitalization in Medicaid beneficiaries with bipolar disorder.
Jing Y; Johnston SS; Fowler R; Bates JA; Forbes RA; Hebden T
J Med Econ; 2011; 14(6):777-86. PubMed ID: 21954966
[TBL] [Abstract][Full Text] [Related]
19. Risperidone long-acting therapy prescribing patterns and their impact on early discontinuation of treatment in a large Medicaid population.
Boaz TL; Constantine RJ; Robst J; Becker MA; Howe AM
J Clin Psychiatry; 2011 Aug; 72(8):1079-85. PubMed ID: 21034690
[TBL] [Abstract][Full Text] [Related]
20. The METEOR study: frequency of metabolic disorders in patients with schizophrenia. Focus on first and second generation and level of risk of antipsychotic drugs.
Falissard B; Mauri M; Shaw K; Wetterling T; Doble A; Giudicelli A; De Hert M
Int Clin Psychopharmacol; 2011 Nov; 26(6):291-302. PubMed ID: 21876442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
